Reuters HealthThe U.S. health regulator has approved Roche Holding AG’s therapy for treating a type of rare cancer called follicular lymphoma.
An influential drug pricing research group said Eisai Co. Ltd. and Biogen Inc.’s new Alzheimer’s disease treatment lecanemab should be priced lower than the drug Aduhelm that was developed by the companies.
Vaccines company Valneva said on Friday that it had completed a regulatory submission step with the United States Food & Drug Administration (FDA) for its single-shot chikungunya vaccine candidate, VLA1553.
Merck & Co. Inc.’s COVID antiviral molnupiravir speeds up recovery but does not reduce the hospitalization or death rate in higher-risk vaccinated adults, detailed data from a large study showed on Thursday.
Mersana Therapeutics Inc. said on Thursday it had signed a deal for developing cancer drugs with Germany’s Merck KGaA that has the potential to generate up to $800 million in milestone payments.
ReutersThe U.S. Food and Drug Administration (FDA) on Thursday approved Gilead Sciences Inc.’s Sunlenca therapy for HIV infections, paving the way for a drug that requires less frequent dosing than existing treatments.
Lexicon Pharmaceuticals’ LX9211 fell short of its primary efficacy endpoint, according to topline data from the Phase II RELIEF-PHN-1 study in post-herpetic neuralgia.
This effort is the first result of the research collaboration established in 2018 between the University of Pennsylvania and BioNTech aimed at developing novel mRNA vaccine candidates for the prevention and treatment of various infectious diseases.
2022 featured pivotal data that could change the landscape in non-alcoholic steatohepatitis, Alzheimer’s disease, sickle cell disease and many more indications.
The vision is three-fold: uncover disease biology with AI; use these insights to design the right molecules; determine the right patient population for clinical trial success.
